Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$43.38 USD

43.38
880,327

+0.37 (0.86%)

Updated Sep 16, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval

by Zacks Equity Research

Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.

    Mark Vickery headshot

    Top Analyst Reports for Allergan, Ecolab & Exelon

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Allergan (AGN), Ecolab (ECL) and Exelon (EXC).

      Mylan Finalizes Settlement Agreement with DOJ for $465M

      by Zacks Equity Research

      Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.

        Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up

        by Zacks Equity Research

        Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.

          Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View

          by Zacks Equity Research

          Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.

            Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2

            by Zacks Equity Research

            Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.

              Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

              by Zacks Equity Research

              Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.

                Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag

                by Zacks Equity Research

                Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.

                  GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance

                  by Zacks Equity Research

                  Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.

                    Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

                    by Zacks Equity Research

                    Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

                      Glaxo (GSK) Beats Q2 Earnings, Misses Sales

                      by Zacks Equity Research

                      Glaxo's (GSK) Q2 earnings beat estimate, with revenue missing the same. Glaxo lowered its core 2017 earnings growth in the quarter, with no Advair generics are launched this year.

                        The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

                          Mark Vickery headshot

                          Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile

                          by Mark Vickery

                          Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), GlaxoSmithKline (GSK), and T-Mobile (TMUS).

                            Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

                            by Zacks Equity Research

                            Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

                              What Lies in Store for Glaxo (GSK) this Earnings Season?

                              by Zacks Equity Research

                              The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

                                Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

                                by Zacks Equity Research

                                Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

                                  Gilead (GILD) Application for HIV Drug Validated in EU

                                  by Zacks Equity Research

                                  Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

                                    Gilead (GILD) Application for HIV Drug Validated in EU

                                    by Zacks Equity Research

                                    Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

                                      Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                                      by Zacks Equity Research

                                      Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                                        Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

                                        by Zacks Equity Research

                                        Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

                                          Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

                                          by Zacks Equity Research

                                          Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

                                            Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

                                            by Zacks Equity Research

                                            Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

                                              Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

                                              by Zacks Equity Research

                                              Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

                                                Glaxo's (GSK) Shingles Candidate Phase III Data Positive

                                                by Zacks Equity Research

                                                GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

                                                  Novartis Announces Positive Results for Cardiovascular Drug

                                                  by Zacks Equity Research

                                                  Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.